PROTEINA
24.7.2024 07:54:26 CEST | Business Wire | Press release
PROTEINA Co., Ltd., in collaboration with Seoul National University (SNU) and Seoul National University Hospital (SNUH), has announced the publication of its latest research in Nature Biomedical Engineering. The study presents a novel approach to personalizing treatment for acute myeloid leukemia (AML) patients by leveraging protein-protein interaction (PPI) profiling to predict drug response.
Critical Need for Personalized AML Treatment
Nearly 90% of AML patients fail to survive without achieving complete remission during initial treatment. ABT-199, in combination with hypomethylating agents, has emerged as a promising therapy by inhibiting the BCL2 protein, a key player in cancer progression. However, varying patient dependency on BCL2 signaling complicates patient selection for this treatment.
Innovative Technique for PPI Profiling
A team of researchers from PROTEINA, SNU, and SNUH tackled this challenge by developing a single-molecule pull-down and co-immunoprecipitation (SMPC) technique. This method quantifies over 20 different types of PPIs and protein expression levels from clinical specimens, using as little as 1 ml of body fluid such as blood or bone marrow aspirate.
The SMPC technique identifies critical PPI links contributing to leukemia cell survival when ABT-199 is administered. The researchers created a prediction model with an AUROC value of 0.94, accurately selecting patients likely to respond to ABT-199 therapy.
Key Findings and Clinical Implications
The study revealed that the BCL2-BAX complex plays a significant role in the survival of AML cells under apoptotic stress induced by ABT-199. Conversely, the BCLxL-BAK complex is linked to resistance, highlighting the drug's selective mechanism.
Through extensive PPI profiling of samples from 32 AML patients, the research identified key PPIs correlating with drug responsiveness. The developed biomarker demonstrated high predictive power, forecasting drug response in 9 out of 10 patients with a sensitivity of 100% and specificity of 83.3%.
Future Directions and Clinical Validation
PROTEINA has acquired venetoclax response prediction technology and patents from SNU and SNUH. The company is currently collaborating with Professor Janghee Woo of Emory University School of Medicine for global clinical validation. "We are thrilled to start this large-scale clinical validation, which is a significant step toward expanding the utility of our platform technology in precision medicine," says Hongwon Lee, Chief Technology Officer at PROTEINA.
Support and Acknowledgements
This research was supported by the National Grants for Leading Scientists of the National Research Foundation of South Korea (NRF) [grant number NRF-2021R1A3B1071354], the Bio Medical Technology Development Program of the NRF [grant number NRF-2018M3A9E2023523], and the Korea Health Technology R&D Project of the Korea Health Industry Development Institute (KHIDI) [grant number HI14C1277].
About PROTEINA Co., Ltd.
PROTEINA Co., Ltd. is a leading biotech company specializing in proteomics, focusing on protein complexes and protein-protein interactions. The company provides cutting-edge analysis services for large pharmaceutical developers, aiming to advance precision medicine through innovative diagnostic technologies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723842885/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Final Investment Decision and Financial Close for Phase 2 of CP2 LNG13.3.2026 15:23:00 CET | Press release
$8.6 billion project financing for CP2 Phase 2 brings project’s total financing to $20.7 billionProject expected to make Venture Global the largest exporter of US LNGUnprecedented milestone of five FIDs in less than 7 years, with over $95 billion in capital markets transactions Today, Venture Global, Inc. (NYSE: VG) is announcing a final investment decision (FID) and successful closing of an $8.6 billion project financing for the second phase of the company’s third project, Venture Global CP2 LNG (CP2). When combined with the Phase One financing for CP2 announced July 2025, this milestone represents the largest standalone project financing in the U.S. bank market.The transaction garnered enormous interest from the world’s leading banks, resulting in over $19 billion of commitments for Phase Two in addition to the previous $34 billion of commitments for Phase One, and required no outside equity investment. “We are extremely proud to have taken FID on the second phase of CP2, our third g
NIQ Launches Beta of New AI-Powered Analytical Capabilities in Ask Arthur13.3.2026 12:00:00 CET | Press release
AI-guided analysis helps brands and retailers turn data into decision-ready insights NIQ (NYSE: NIQ), a global leader in consumer intelligence, has launched new AI-powered analytical capabilities in beta within Ask Arthur on the NIQ Discover platform. The expanded experience guides users through end-to-end analysis—helping them identify what matters in the data, understand why trends are occurring, and turn insights into clear, shareable narratives with recommended next steps. As organizations navigate increasing data complexity, the ability to move quickly from insight to action has become essential. Ask Arthur helps shorten analytical processes that once took days or weeks into minutes by surfacing the key drivers behind performance changes and generating decision-ready insights directly within Discover. By connecting analysis, explanation, and storytelling in a single experience, users can move seamlessly from understanding what is happening in the data to determining what to do nex
Reply at NVIDIA GTC: Digital Twins and Physical AI Driving the Next Stage of Industrial Value Creation13.3.2026 11:24:00 CET | Press release
Reply [EXM, STAR: REY] will be present at NVIDIA GTC from 16 to 19 March 2026 in San Jose, California, showcasing how companies can optimise production and logistics processes, scale robotics and sustainably increase industrial performance using digital twin technology and physical AI. The conference is regarded as the most important international meeting point for AI developers, researchers and decision makers. This year, more than 30,000 participants from over 190 countries are expected to attend. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260313000399/en/ By attending NVIDIA GTC, Reply is showcasing how digital simulation and physical automation are already being integrated in practice. Projects for the Otto Group and the industrial edge domain show how physical AI and precise digital twins work together to create new opportunities for industrial value generation. The focus will be on two concrete use cases that demon
Klarna Board Chair Michael Moritz Acquires 3.47 Million Shares for $50 Million13.3.2026 11:05:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today discloses the following transactions by the Chair of its Board of Directors and Chief Product & Design Officer, filed with the U.S. Securities and Exchange Commission on Form 3. Share Purchases Michael Moritz, Chairman, through an associated entity, purchased 3,472,845 ordinary shares between March 3 and March 11, 2026, at an aggregate consideration of $49,913,138.73. David Fock, Chief Product & Design Officer, purchased 27,000 ordinary shares on March 9, 2026, for an aggregate consideration of $388,552.14. Share Sales David Sandström, Chief Marketing Officer, sold 32,703 shares on March 9, 2026, pursuant to a Rule 10b5-1 trading plan, established in 2025. David Sykes, Chief Commercial Officer, sold 23,799 shares on March 13, 2026, pursuant to a separately established Rule 10b5-1 trading plan, established in 2025. Form 3 filings for all transactions are available on the SEC's EDGAR database atwww.sec.gov. Forward-Looking Statements This press release
Intertek Launches Comprehensive Digital Product Passport Services13.3.2026 10:00:00 CET | Press release
Supporting circular economy and regulatory compliance Intertek, a leading Total Quality Assurance provider to industries worldwide, has announced the launch of its enhanced Digital Product Passport (DPP) suite of services. This includes a comprehensive advisory service designed to help manufacturers, brands and retailers navigate the fast-evolving regulatory and sustainability landscape associated with digital product passports and circular economy compliance. Mark Thomas, Executive Vice President, Global Sustainability, Assurance, Agri World and Food at Intertek, said: “With the introduction of regulatory frameworks for improving the sustainability performance of products, companies are facing mounting pressure to implement robust systems for transparency, traceability and sustainability reporting globally. This shift marks a significant regulatory milestone, requiring organisations to strengthen data governance, engage suppliers more effectively and demonstrate credible, verifiable s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom